These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38914283)

  • 1. Characterization and noncovalent inhibition of the K63-deubiquitinase activity of SARS-cov-2 PLpro.
    Liu X; Zheng M; Zhang H; Feng B; Li J; Zhang Y; Zhang J; Zhao N; Li C; Song N; Song B; Yang D; Chen J; Qi A; Zhao L; Luo C; Zang Y; Liu H; Li J; Zhang B; Zhou Y; Zheng J
    Antiviral Res; 2024 Aug; 228():105944. PubMed ID: 38914283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity.
    Shin D; Mukherjee R; Grewe D; Bojkova D; Baek K; Bhattacharya A; Schulz L; Widera M; Mehdipour AR; Tascher G; Geurink PP; Wilhelm A; van der Heden van Noort GJ; Ovaa H; Müller S; Knobeloch KP; Rajalingam K; Schulman BA; Cinatl J; Hummer G; Ciesek S; Dikic I
    Nature; 2020 Nov; 587(7835):657-662. PubMed ID: 32726803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization and Noncovalent Inhibition of the Deubiquitinase and deISGylase Activity of SARS-CoV-2 Papain-Like Protease.
    Freitas BT; Durie IA; Murray J; Longo JE; Miller HC; Crich D; Hogan RJ; Tripp RA; Pegan SD
    ACS Infect Dis; 2020 Aug; 6(8):2099-2109. PubMed ID: 32428392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aloin isoforms (A and B) selectively inhibits proteolytic and deubiquitinating activity of papain like protease (PLpro) of SARS-CoV-2 in vitro.
    Lewis DSM; Ho J; Wills S; Kawall A; Sharma A; Chavada K; Ebert MCCJC; Evoli S; Singh A; Rayalam S; Mody V; Taval S
    Sci Rep; 2022 Feb; 12(1):2145. PubMed ID: 35140265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ciclesonide Inhibits SARS-CoV-2 Papain-Like Protease in Vitro.
    Kiba Y; Tanikawa T; Kitamura M
    Biol Pharm Bull; 2024; 47(5):965-966. PubMed ID: 38763750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Losartan Inhibits SARS-CoV-2 Replication in Vitro.
    Nejat R; Sadr AS; Freitas B; Crabttree J; Pegan SD; Tripp RA; Najafi D
    J Pharm Pharm Sci; 2021; 24():390-399. PubMed ID: 34319871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reconstruction of the unbinding pathways of new inhibitors of the SARS-CoV-2 papain-like protease using molecular dynamics simulation.
    Rahebi P; Aryapour H
    J Biomol Struct Dyn; 2024 Sep; 42(14):7501-7514. PubMed ID: 37505097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unraveling antiviral efficacy of multifunctional immunomodulatory triterpenoids against SARS-COV-2 targeting main protease and papain-like protease.
    Choudhary S; Nehul S; Singh A; Panda PK; Kumar P; Sharma GK; Tomar S
    IUBMB Life; 2024 May; 76(5):228-241. PubMed ID: 38059400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-Toxic Dimeric Peptides Derived from the Bothropstoxin-I Are Potent SARS-CoV-2 and Papain-like Protease Inhibitors.
    Freire MCLC; Noske GD; Bitencourt NV; Sanches PRS; Santos-Filho NA; Gawriljuk VO; de Souza EP; Nogueira VHR; de Godoy MO; Nakamura AM; Fernandes RS; Godoy AS; Juliano MA; Peres BM; Barbosa CG; Moraes CB; Freitas-Junior LHG; Cilli EM; Guido RVC; Oliva G
    Molecules; 2021 Aug; 26(16):. PubMed ID: 34443484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism and inhibition of the papain-like protease, PLpro, of SARS-CoV-2.
    Klemm T; Ebert G; Calleja DJ; Allison CC; Richardson LW; Bernardini JP; Lu BG; Kuchel NW; Grohmann C; Shibata Y; Gan ZY; Cooney JP; Doerflinger M; Au AE; Blackmore TR; van der Heden van Noort GJ; Geurink PP; Ovaa H; Newman J; Riboldi-Tunnicliffe A; Czabotar PE; Mitchell JP; Feltham R; Lechtenberg BC; Lowes KN; Dewson G; Pellegrini M; Lessene G; Komander D
    EMBO J; 2020 Sep; 39(18):e106275. PubMed ID: 32845033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SARS-CoV-2 Papain-Like Protease Potential Inhibitors-In Silico Quantitative Assessment.
    Stasiulewicz A; Maksymiuk AW; Nguyen ML; Bełza B; Sulkowska JI
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33921228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of novel human USP2 inhibitor and its putative role in treatment of COVID-19 by inhibiting SARS-CoV-2 papain-like (PLpro) protease.
    Mirza MU; Ahmad S; Abdullah I; Froeyen M
    Comput Biol Chem; 2020 Dec; 89():107376. PubMed ID: 32979815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of potent and selective inhibitors targeting the papain-like protease of SARS-CoV-2.
    Shan H; Liu J; Shen J; Dai J; Xu G; Lu K; Han C; Wang Y; Xu X; Tong Y; Xiang H; Ai Z; Zhuang G; Hu J; Zhang Z; Li Y; Pan L; Tan L
    Cell Chem Biol; 2021 Jun; 28(6):855-865.e9. PubMed ID: 33979649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitory effects of senkyuchachosan on SARS-CoV-2 papain-like protease activity in vitro.
    Kiba Y; Tanikawa T; Hayashi T; Yokogawa T; Sano A; Suzuki R; Kitamura M
    J Nat Med; 2024 Jun; 78(3):784-791. PubMed ID: 38512650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Postinfection treatment with a protease inhibitor increases survival of mice with a fatal SARS-CoV-2 infection.
    Dampalla CS; Zheng J; Perera KD; Wong LR; Meyerholz DK; Nguyen HN; Kashipathy MM; Battaile KP; Lovell S; Kim Y; Perlman S; Groutas WC; Chang KO
    Proc Natl Acad Sci U S A; 2021 Jul; 118(29):. PubMed ID: 34210738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel robust inhibitor of papain-like protease (PLpro) as a COVID-19 drug.
    Soleimani Asl S; Roozbahani MH
    J Biomol Struct Dyn; 2024 Aug; 42(13):6863-6870. PubMed ID: 37578047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploring Cannabinoids as Potential Inhibitors of SARS-CoV-2 Papain-like Protease: Insights from Computational Analysis and Molecular Dynamics Simulations.
    Holmes J; Islam SM; Milligan KA
    Viruses; 2024 May; 16(6):. PubMed ID: 38932170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of potential plant-based inhibitor against viral proteases of SARS-CoV-2 through molecular docking, MM-PBSA binding energy calculations and molecular dynamics simulation.
    Gogoi B; Chowdhury P; Goswami N; Gogoi N; Naiya T; Chetia P; Mahanta S; Chetia D; Tanti B; Borah P; Handique PJ
    Mol Divers; 2021 Aug; 25(3):1963-1977. PubMed ID: 33856591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of Nsp3 papain-like protease.
    Lim CT; Tan KW; Wu M; Ulferts R; Armstrong LA; Ozono E; Drury LS; Milligan JC; Zeisner TU; Zeng J; Weissmann F; Canal B; Bineva-Todd G; Howell M; O'Reilly N; Beale R; Kulathu Y; Labib K; Diffley JFX
    Biochem J; 2021 Jul; 478(13):2517-2531. PubMed ID: 34198325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The complex structure of GRL0617 and SARS-CoV-2 PLpro reveals a hot spot for antiviral drug discovery.
    Fu Z; Huang B; Tang J; Liu S; Liu M; Ye Y; Liu Z; Xiong Y; Zhu W; Cao D; Li J; Niu X; Zhou H; Zhao YJ; Zhang G; Huang H
    Nat Commun; 2021 Jan; 12(1):488. PubMed ID: 33473130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.